Unlike the pro-tumorigenic release described above, this HMGB1 acts on tumor-associated macrophages (TAMs) via the RAGE-NF-κB-NLRP3 inflammasome pathway, driving them toward an M1-like, anti-tumor phenotype. Here, NLRP3 is linked to neoplasm.